Top brand choice
Strength | Pack Size | Qty | |
---|---|---|---|
Strength
5g/50ml
|
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Privigen is a ready-to-use, 10% liquid solution of Immunoglobulin (Human) intended for intravenous administration. It is approved for the treatment of primary humoral immunodeficiency (PI) and chronic immune thrombocytopenic purpura (ITP) in adults. Privigen delivers a broad spectrum of IgG antibodies that reflect the diversity of the human immune response, offering both infection prevention and immunomodulatory effects. The formulation is stabilized with L-proline and is free from preservatives and sucrose, minimizing the risk of renal complications and other adverse effects. Privigen is produced using a proprietary manufacturing process designed to ensure high purity and viral safety.
Fact Table | |
Formula | Polyclonal IgG (human plasma-derived) |
License | US FDA, EMA |
Bioavailability | 100% (intravenous) |
Legal status | Prescription only (Rx) |
Chemical Name | Immunoglobulin G (Human) |
Elimination half-life | 25–35 days |
Dosage (Strength) | 10% solution (100 mg/mL) |
Pregnancy | Use only if clearly needed |
Brands | Privigen |
Protein binding | Not applicable (endogenous protein) |
PubChem CID | 16133278 |
MedlinePlus | a610019 |
ChEBI | 16763 |
ATC code | J06BA02 |
DrugBank | DB13100 |
KEGG | D02259 |
Routes of administration | Intravenous (IV) |
Privigen is administered intravenously by a healthcare professional. For primary immunodeficiency, doses are typically given every 3 to 4 weeks, depending on the patient’s clinical status and IgG trough levels. In the treatment of ITP, higher doses may be administered over a short period. Infusion should begin at a slow rate and may be increased gradually if well tolerated. Patients must be monitored closely during infusion, particularly during the first administration. Pre-medication may be considered for patients with a history of infusion-related reactions.
Each milliliter of Privigen contains 100 mg of Immunoglobulin G (IgG), 250 mg of L-proline as a stabilizer, and water for injection. The solution has a pH of approximately 4.8 and contains trace amounts of IgA. It is free of preservatives, sucrose, and latex.
Privigen is contraindicated in individuals with a history of anaphylactic or severe systemic reactions to human immunoglobulin products. It is also contraindicated in patients with hyperprolinemia due to the presence of L-proline. Patients with known IgA deficiency who have anti-IgA antibodies and a history of hypersensitivity should not receive this product.
Use with caution in patients with renal impairment, diabetes mellitus, risk factors for thromboembolic events, or pre-existing volume overload. Privigen should be administered at the lowest effective dose and infusion rate. Baseline and ongoing assessments of renal function, hydration status, and blood viscosity are recommended in at-risk individuals. Immunoglobulin therapy may interfere with the immune response to live virus vaccines. Patients should be informed of the signs of severe adverse effects and instructed to report them promptly.
Common adverse reactions to Privigen may include:
Serious but rare side effects can include thromboembolic events, aseptic meningitis, renal dysfunction, and hemolysis. Immediate medical evaluation is warranted in the presence of symptoms suggestive of a serious reaction.